dslim (double stem loop immunomodulator) (MOLOGEN Inc)
90
Structured Review
MOLOGEN Inc
dslim (double stem loop immunomodulator)
Dslim (Double Stem Loop Immunomodulator), supplied by MOLOGEN Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/immunomodulation/dslim++double+stem+loop+immunomodulator/us11760796-229-5-11
Average 90 stars, based on 1 article reviews
Dslim (Double Stem Loop Immunomodulator), supplied by MOLOGEN Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/immunomodulation/dslim++double+stem+loop+immunomodulator/us11760796-229-5-11
Average 90 stars, based on 1 article reviews
dslim (double stem loop immunomodulator) - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: Compositions and methods for treatment of diseases involving CXCL1 function Article Snippet: A CpG TLR9 antagonist is Article Title: Immunotherapy with B*07 restricted peptides and combination of peptides against cancers and related methods Article Snippet: A CpG TLR9 antagonist is Article Title: Peptides and combination of peptides for use in immunotherapy against various tumors Article Snippet: A CpG TLR9 antagonist is Article Title: GINS2 peptide and T cells for use in immunotherapeutic treatment of various cancers Article Snippet: A CpG TLR9 antagonist is Article Title: Powerful MHC-class II peptides derived from survivin Article Snippet: A CpG TLR9 antagonist is Article Title: Peptides for use in immunotherapy against cancers Article Snippet: A CpG TLR9 antagonist is Article Title: Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers Article Snippet: A CpG TLR9 antagonist is Article Title: B*44 restricted peptides for use in immunotherapy against cancers and related methods Article Snippet: No. 6,406,705 B1 describes the combined use of CpG oligonucleotides, non-nucleic acid adjuvants and an antigen to induce an antigen-specific immune response. |